

## India's GVSAP collaborates with China-based Biocytogen to accelerate biopharma innovation

17 May 2024 | News

**The alliance aims to expedite the innovation of scientific discoveries**



GV Safety Assessment Platform (GVSAP), a leading integrated R&D enabler offering comprehensive preclinical research solutions, has announced a groundbreaking partnership with China-based company Biocytogen.

This collaboration marks a significant advancement in biomedical research, aimed at bolstering the R&D endeavours of Indian researchers by democratising cutting-edge tools and technologies.

Through this strategic alliance, Indian biomedical researchers will gain access to Biocytogen's expertise in providing humanised research models, other off-the-shelf models and products, and Gene Targeting Services offered under Biocytogen's sub-brand BioMice.

Headquartered at Genome Valley, Hyderabad, GVSAP, a subsidiary of GV Research Platform (GVRP), boasts AAALAC International and OECD-GLP compliant facilities spanning over 30,000 square feet. With a state-of-the-art modern vivarium featuring dedicated SPF breeding and preclinical testing areas, GVSAP ensures the highest standards of research integrity and animal welfare.

Kalyan Korisapati, Co-Founder & CEO of GVRP, expressed his enthusiasm, stating, "Biocytogen's expertise in creating engineered models that mimic the interaction between drug and human targets aims to provide the Indian biopharma community with convenient access to precision research."

Yuelei Shen, CEO of Biocytogen, emphasised the partnership's potential, stating, "With India's rising prominence in biopharma R&D, it's a pivotal hub for advanced solutions like humanised mice. By leveraging GVSAP's extensive reach in the Indian biopharma community, we are poised to catalyse pioneering discoveries and accelerate Indian biomedical research through this collaboration."